Atara Biotherapeutics Company Description

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.

Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.

The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.

Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Atara Biotherapeutics, Inc.

Country	United States
Founded	2012
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	153
CEO	Anhco Nguyen

Contact Details

Address: 1280 Rancho Conejo Blvd Thousand Oaks, Delaware 91320 United States
Phone	805 623 4211
Website	atarabio.com

Stock Details

Ticker Symbol	0HIY
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US0465131078
SIC Code	2836

Key Executives

Name	Position
Anhco Nguyen	Chief Executive Officer
Yanina Grant-Huerta	Chief Financial Officer
Alex Chapman	Head of Investor Relations